Formerly known as MacroPore, Inc. and MacroPore Biosurgery, Inc. - the latter traded on the Frankfort Exchange (XMP) , Cytori Therapeutics, Inc. engages in developing and commercializing stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery, and serious, chronic, and life threatening conditions. Cyrtori has developed the Celution® System family of medical devices and instruments which are being sold in the European and Asian cosmetic and reconstructive surgery markets. Regulatory approval for the devices are being sought in the United States. Cytori's StemSource® product line is sold globally for cell banking and research applications. In addition, it operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Cytori Therapeutics also manufactures macropore biosurgery products that include HYDROSORB family of spine and orthopedic implant products and thin film bioresorbable soft tissue separation implant products. It has strategic joint venture with Olympus Corporation to develop to manufacture future generation devices based on its Celution system. Besides its headquarters in San Diego, California, Cytori also maintains offices in Switzerland, Japan, and India